<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02802228</url>
  </required_header>
  <id_info>
    <org_study_id>CPI-IFE-005</org_study_id>
    <nct_id>NCT02802228</nct_id>
  </id_info>
  <brief_title>Study to Assess Safety and Efficacy of Ifetroban for Treatment of Portal Hypertension in Cirrhotic Patients</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled Pilot Study to Assess the Safety and Efficacy of Ifetroban for the Treatment of Portal Hypertension in Cirrhotic Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cumberland Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cumberland Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This placebo-controlled study will assess the safety and efficacy of a 90-day course of
      treatment with ifetroban for portal hypertension in cirrhotic patients
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 6, 2017</start_date>
  <completion_date type="Anticipated">September 2018</completion_date>
  <primary_completion_date type="Anticipated">August 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety (incidence and severity of adverse events)</measure>
    <time_frame>Through 97 days</time_frame>
    <description>safety will be assessed by the incidence and severity of adverse events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hepatic venous pressure gradient (HVPG)</measure>
    <time_frame>Baseline and 90 days</time_frame>
    <description>The HVPG will be measured through Day 90 and will be compared to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Aspartate Aminotransferase (AST)</measure>
    <time_frame>Baseline and 90 days</time_frame>
    <description>AST values through Day 90 will be compared to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Alanine Aminotransferase (ALT)</measure>
    <time_frame>Baseline and 90 days</time_frame>
    <description>ALT values through Day 90 will be compared to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>APRI</measure>
    <time_frame>Baseline and 90 days</time_frame>
    <description>The Aspartate Aminotransferase/Platelet Ratio through Day 90 will be compared to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Variceal bleeds (occurrence of variceal bleeds)</measure>
    <time_frame>Through Day 97</time_frame>
    <description>The number of variceal bleeds during the treatment and follow-up periods will be evaluated</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Portal Hypertension</condition>
  <condition>Liver Cirrhosis</condition>
  <arm_group>
    <arm_group_label>Ifetroban</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>90 day course of oral ifetroban following intravenous loading dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>90 day course of placebo following intravenous dose of D5W</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ifetroban</intervention_name>
    <description>thromboxane prostanoid receptor antagonist delivered as infusion and oral capsule</description>
    <arm_group_label>Ifetroban</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>matched placebo delivered as infusion and oral capsule</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  liver cirrhosis

          -  baseline HVPG &gt;= 8 mmHg and &lt;= 18 mmHg

          -  stable liver function enzymes

        Exclusion Criteria:

          -  portal or splenic vein thrombosis

          -  TIPS or portocaval shunt

          -  variceal bleed in last 2 months

          -  hemodialysis

          -  Child-Pugh Score &gt;= 12

          -  MELD-Na &gt;= 20

          -  Acute kidney injury, Chronic kidney disease and/or Serum Creatinine &gt;= 2.0 mg/dL

          -  current alcohol consumption &gt; 2 drinks per day

          -  PLT &lt; 60 x 10^3/uL

          -  A change in statin therapy in the last 3 months

          -  Current HBV or HCV therapy; or planned initiation of therapy during the treatment
             period

          -  Myocardial infarction within 30 days

          -  History of bleeding diathesis or current (within previous 14 days) or planned use of
             anticoagulant or antiplatelet drugs including aspirin
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Don Rockey, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of South Carolina</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jerry Fox, DVM</last_name>
    <phone>6152550068</phone>
    <email>jfox@cumberlandpharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Tampa General Medical Group</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33606</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michele Reilly</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Indiana University</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nina Garrett</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Ohio State University Wexner Medical Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Angela Sipes</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Linsay Totin</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Baylor University Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tanya Narithookil</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Virginia Commonwealth University Medical Center</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephanie Taylor</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 9, 2016</study_first_submitted>
  <study_first_submitted_qc>June 13, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 16, 2016</study_first_posted>
  <last_update_submitted>April 16, 2018</last_update_submitted>
  <last_update_submitted_qc>April 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Hypertension, Portal</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ifetroban</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

